Paul R. Freund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paul R. Freund has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amir Khashayar Varkouhi
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
1 shared publication - Edward Margolin
University of Toronto Faculty of Medicine
1 shared publication - Ian M. MacDonald
Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Ioannis S. Dimopoulos
Department of Ophthalmology, University of Ottawa, Ottawa, Canada
1 shared publication - Stephanie C. Hoang
Genetics & Genomics, Alberta Precision Laboratories, Edmonton, AB T6G 2H7, Canada
1 shared publication - Tania Bubela
Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
1 shared publication
Latest Publications
- 25 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e240463
Lipomatosis and optic neuropathy clinches the diagnosis of myoclonic epilepsy with ragged red fibres (MERRF) syndrome
We present a rare case of myoclonic epilepsy with ragged red fibres with high level of heteroplasmy presenting with optic neuropathy and a rare phenotype of lipomatosis. Cutaneous lipomas are typically thought of as a benign/isolated entity and this case emphasises importance of considering mitochondrial disease in all patients with lipomatosis especially in the presence of other systemic abnormalities.
- 25 March 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (3) , e240463
Lipomatosis and optic neuropathy clinches the diagnosis of myoclonic epilepsy with ragged red fibres (MERRF) syndrome
We present a rare case of myoclonic epilepsy with ragged red fibres with high level of heteroplasmy presenting with optic neuropathy and a rare phenotype of lipomatosis. Cutaneous lipomas are typically thought of as a benign/isolated entity and this case emphasises importance of considering mitochondrial disease in all patients with lipomatosis especially in the presence of other systemic abnormalities.
- 8 February 2016
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 37 (3) , 267-275
Choroideremia research: Report and perspectives on the second international scientific symposium for choroideremia
Purpose: To discuss progress in research on choroideremia (CHM) and related retinopathies with special emphasis on gene therapy approaches. Methods: Biomedical and clinical researchers from across the world as well as representatives of the social science research community were convened to the 2nd International Scientific Symposium for Choroideremia in Denver, Colorado in June 2014 to enhance our understanding of CHM and accelerate the translation of research to clinical application for the benefit of those affected by CHM. Results: Pre-clinical research using cell and animal models continues to further our understanding in the pathogenesis of CHM as well as to demonstrate proof-of-concept for gene transfer strategies. With the advent of modern imaging technology, better outcome measures are being defined for upcoming clinical trials. Results from the first gene therapy trial in CHM show promise, with sustained visual improvement over 6 months post-treatment. Current and next-generation gene transfer approaches may make targeted vector delivery possible in the future for CHM and other inherited retinal diseases. Conclusions: While no accepted therapies exist for CHM, promising approaches using viral-vectored gene therapy and cell therapies are entering clinical trials for eye diseases, with gene therapy trials underway for CHM.
- 8 February 2016
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 37 (3) , 267-275
Choroideremia research: Report and perspectives on the second international scientific symposium for choroideremia
Purpose: To discuss progress in research on choroideremia (CHM) and related retinopathies with special emphasis on gene therapy approaches. Methods: Biomedical and clinical researchers from across the world as well as representatives of the social science research community were convened to the 2nd International Scientific Symposium for Choroideremia in Denver, Colorado in June 2014 to enhance our understanding of CHM and accelerate the translation of research to clinical application for the benefit of those affected by CHM. Results: Pre-clinical research using cell and animal models continues to further our understanding in the pathogenesis of CHM as well as to demonstrate proof-of-concept for gene transfer strategies. With the advent of modern imaging technology, better outcome measures are being defined for upcoming clinical trials. Results from the first gene therapy trial in CHM show promise, with sustained visual improvement over 6 months post-treatment. Current and next-generation gene transfer approaches may make targeted vector delivery possible in the future for CHM and other inherited retinal diseases. Conclusions: While no accepted therapies exist for CHM, promising approaches using viral-vectored gene therapy and cell therapies are entering clinical trials for eye diseases, with gene therapy trials underway for CHM.